X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA TORRENT PHARMA AJANTA PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 21.4 43.8 48.9% View Chart
P/BV x 5.0 6.0 83.3% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 AJANTA PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
TORRENT PHARMA
Mar-18
AJANTA PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,8181,550 117.3%   
Low Rs1,1061,144 96.7%   
Sales per share (Unadj.) Rs239.5354.7 67.5%  
Earnings per share (Unadj.) Rs52.840.1 131.7%  
Cash flow per share (Unadj.) Rs59.564.2 92.7%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs230.0273.1 84.2%  
Shares outstanding (eoy) m88.77169.22 52.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.13.8 160.8%   
Avg P/E ratio x27.733.6 82.4%  
P/CF ratio (eoy) x24.621.0 117.2%  
Price / Book Value ratio x6.44.9 128.9%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m129,782227,897 56.9%   
No. of employees `0006.814.7 46.2%   
Total wages/salary Rs m3,76511,353 33.2%   
Avg. sales/employee Rs Th3,128.44,083.0 76.6%   
Avg. wages/employee Rs Th554.0772.3 71.7%   
Avg. net profit/employee Rs Th689.7461.3 149.5%   
INCOME DATA
Net Sales Rs m21,25860,021 35.4%  
Other income Rs m2422,988 8.1%   
Total revenues Rs m21,49963,009 34.1%   
Gross profit Rs m6,58413,493 48.8%  
Depreciation Rs m5964,086 14.6%   
Interest Rs m43,085 0.1%   
Profit before tax Rs m6,2269,310 66.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5392,529 60.9%   
Profit after tax Rs m4,6866,781 69.1%  
Gross profit margin %31.022.5 137.8%  
Effective tax rate %24.727.2 91.0%   
Net profit margin %22.011.3 195.1%  
BALANCE SHEET DATA
Current assets Rs m12,23652,623 23.3%   
Current liabilities Rs m3,46152,022 6.7%   
Net working cap to sales %41.31.0 4,119.4%  
Current ratio x3.51.0 349.6%  
Inventory Days Days60120 50.3%  
Debtors Days Days8476 110.8%  
Net fixed assets Rs m11,14085,016 13.1%   
Share capital Rs m177846 20.9%   
"Free" reserves Rs m20,23745,376 44.6%   
Net worth Rs m20,41446,222 44.2%   
Long term debt Rs m1041,115 0.0%   
Total assets Rs m24,486142,432 17.2%  
Interest coverage x1,519.44.0 37,814.7%   
Debt to equity ratio x00.9 0.1%  
Sales to assets ratio x0.90.4 206.0%   
Return on assets %19.26.9 276.5%  
Return on equity %23.014.7 156.5%  
Return on capital %30.514.2 214.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66714,580 80.0%   
Fx outflow Rs m1,6163,600 44.9%   
Net fx Rs m10,05210,980 91.5%   
CASH FLOW
From Operations Rs m2,8548,942 31.9%  
From Investments Rs m-2,604-47,070 5.5%  
From Financial Activity Rs m-234,174 -0.0%  
Net Cashflow Rs m248-3,655 -6.8%  

Share Holding

Indian Promoters % 73.8 71.5 103.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 7.0 22.1%  
FIIs % 7.6 12.6 60.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.8 193.2%  
Shareholders   20,968 26,511 79.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  MERCK LTD  PFIZER  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 260 Points Down; TCS & Infosys Top Losers(12:30 pm)

Stock markets in India are presently trading lower, tracking weakness in their global peers. Among the sectoral indices, IT stocks and metal stocks are witnessing maximum selling pressure.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 21, 2018 03:09 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - VENUS REMEDIES COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS